Stock Track | ImmunityBio Soars 29.5% on Promising Cancer Therapy Data and 700% Revenue Growth

Stock Track01-16

ImmunityBio, Inc. (IBRX) surged 29.5% intraday on Friday, driven by groundbreaking clinical trial results and explosive revenue growth for its flagship drug, Anktiva.

The biotech company announced durable complete responses of up to 15 months in a chemotherapy-free CD19 CAR-NK cell therapy trial for Waldenstrom lymphoma, with 100% disease control observed. The outpatient treatment showed no serious adverse events, bolstering investor confidence in its pipeline.

Preliminary earnings revealed a 700% year-over-year revenue jump for Anktiva, reaching $113 million in 2025, alongside recent regulatory approvals in Saudi Arabia for non-small cell lung cancer. The dual catalysts of clinical success and commercial momentum fueled the stock's rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149155685?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 23:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149155685","market":"us","top_or_hot":-1,"title":"Stock Track | ImmunityBio Soars 29.5% on Promising Cancer Therapy Data and 700% Revenue Growth","media":"Stock Track","content":"<p>ImmunityBio, Inc. (IBRX) surged 29.5% intraday on Friday, driven by groundbreaking clinical trial results and explosive revenue growth for its flagship drug, Anktiva.</p><p>The biotech company announced durable complete responses of up to 15 months in a chemotherapy-free CD19 CAR-NK cell therapy trial for Waldenstrom lymphoma, with 100% disease control observed. The outpatient treatment showed no serious adverse events, bolstering investor confidence in its pipeline.</p><p>Preliminary earnings revealed a 700% year-over-year revenue jump for Anktiva, reaching $113 million in 2025, alongside recent regulatory approvals in Saudi Arabia for non-small cell lung cancer. The dual catalysts of clinical success and commercial momentum fueled the stock's rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio Soars 29.5% on Promising Cancer Therapy Data and 700% Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio Soars 29.5% on Promising Cancer Therapy Data and 700% Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-16 23:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmunityBio, Inc. (IBRX) surged 29.5% intraday on Friday, driven by groundbreaking clinical trial results and explosive revenue growth for its flagship drug, Anktiva.</p><p>The biotech company announced durable complete responses of up to 15 months in a chemotherapy-free CD19 CAR-NK cell therapy trial for Waldenstrom lymphoma, with 100% disease control observed. The outpatient treatment showed no serious adverse events, bolstering investor confidence in its pipeline.</p><p>Preliminary earnings revealed a 700% year-over-year revenue jump for Anktiva, reaching $113 million in 2025, alongside recent regulatory approvals in Saudi Arabia for non-small cell lung cancer. The dual catalysts of clinical success and commercial momentum fueled the stock's rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1149155685","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149155685","pubTimestamp":1768576470,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ImmunityBio, Inc. (IBRX) surged 29.5% intraday on Friday, driven by groundbreaking clinical trial results and explosive revenue growth for its flagship drug, Anktiva.The biotech company announced...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"个股追踪|ImmunityBio飙升29.5%，因癌症治疗数据看好，营收增长700%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio, Inc. (IBRX) surged 29.5% intraday on Friday, driven by groundbreaking clinical trial results and explosive revenue growth for its flagship drug, Anktiva.The biotech company announced durable complete responses of up to 15 months in a chemotherapy-free CD19 CAR-NK cell therapy trial for Waldenstrom lymphoma, with 100% disease control observed. The outpatient treatment showed no serious adverse events, bolstering investor confidence in its pipeline.Preliminary earnings revealed a 700% year-over-year revenue jump for Anktiva, reaching $113 million in 2025, alongside recent regulatory approvals in Saudi Arabia for non-small cell lung cancer. The dual catalysts of clinical success and commercial momentum fueled the stock's rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149155685","isCrawlerRequest":true}